Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit
Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE:...
Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services
The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...
InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment
China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...
Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that ASC40 (denifanstat), a fatty acid synthase...
HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates
China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech...
Sichuan Biokin’s BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China’s CDE
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its bispecific antibody drug conjugate...
Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer
US pharmaceutical giant Merck & Co., Inc. (MRK, NYSE: MRK) has announced that the Phase...
Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment
German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food...
Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives
Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc.,...
Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange
China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...
Pfizer Halts Development of Sisunatovir, an RSV Antiviral, After Phase II/III Trials
U.S. pharmaceutical giant Pfizer (NYSE: PFE) has decided to discontinue the development of sisunatovir, an...
Biogen’s China Unit Gets Conditional NMPA Nod for Qalsody (Tofersen) in ALS Treatment
Biogen (NASDAQ: BIIB)’s Chinese subsidiary has announced that it has received conditional approval from the...
Joincare Pharmaceutical Secures NMPA Approval for Triptorelin Microspheres to Treat Endometriosis
China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...
CSPC Pharmaceutical Secures NMPA Approval for Omalizumab Biosimilar
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received marketing approval...
Ningbo Menovo Pharmaceutical Partners with Nanjing Huawe Medicine for High-End Product Development
Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has entered into a strategic partnership with Nanjing...
CSPC Pharmaceutical’s ADC CPO301 Earns Second Fast-Track Designation in the US for NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
Bio-Thera Solutions Ltd Strikes Licensing Deal with Gedeon Richter for BAT1706 Biosimilar
Guangzhou-based Bio-Thera Solutions Ltd has announced a licensing agreement with Hungary’s Gedeon Richter Plc for...
Jiangsu Aidea Pharmaceutical Secures NMPA Approval for Expanded Indication of Fubangde in HIV Treatment
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Ascentage Pharma Receives Approval for Two Phase III Trials of APG-2449 in NSCLC
China-based biopharmaceutical company Ascentage Pharma (HKG: 6855) has announced that it has received approval from...
MicroPort Endovascular MedTech’s Fiber Wool Plug Spring Coil Gains NMPA Marketing Approval
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has received marketing approval from the National...